Correction to: Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models (Stem Cell Research & Therapy, (2014), 5, 2, (46), 10.1186/scrt440);Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models

Stem Cell Research and Therapy

Volumn 5, Issue 2, 2014, Pages

  Blurton Jones, Mathew ^a   Spencer, Brian ^d   Michael, Sara ^d   Castello, Nicholas A ^a   Agazaryan, Andranik A ^a   Davis, Joy L ^a   Müller, Franz Josef ^b,c   Loring, Jeanne F ^b   Masliah, Eliezer ^d   Laferla, Frank M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PLACEBO;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL BASED GENE THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; EXPRESSION VECTOR; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL PLASTICITY; NERVE PROJECTION; NEURAL STEM CELL TRANSPLANTATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RISK REDUCTION; SENSORY NERVE; SUBICULUM; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEURAL STEM CELL; PATHOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEPRILYSIN; NEURAL STEM CELLS; STEM CELL TRANSPLANTATION; TRANSFECTION;

EID: 84899452093     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-024-03702-7     Document Type: Erratum

References (30)

1. Alzheimer's disease facts and figures. W Thies, L Bleiler, Alzheimers Dement 2011 2011 208 244
2. MJ Prince, CP Ferri, R Sousa, E Albanese, WS Ribeiro, M Honyashiki, World Alzheimer Report 2009: The Global Prevalence of Dementia London: Alzheimer Disease International 2009 Available at: http://www.alz.co.uk/research/files/ WorldAlzheimerReport.pdf
3. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. M Blurton-Jones, M Kitazawa, H Martinez-Coria, NA Castello, FJ Muller, JF Loring, TR Yamasaki, WW Poon, KN Green, FM LaFerla, Proc Natl Acad Sci U S A 2009 106 13594 13599 10.1073/pnas.0901402106 19633196
4. Cell-mediated neuroprotection in a mouse model of human tauopathy. DW Hampton, DJ Webber, B Bilican, M Goedert, MG Spillantini, S Chandran, J Neurosci 2010 30 9973 9983 10.1523/JNEUROSCI.0834-10.2010 20668182
5. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation. HJ Lee, JK Lee, H Lee, JE Carter, JW Chang, W Oh, YS Yang, JG Suh, BH Lee, HK Jin, JS Bae, Neurobiol Aging 2010 33 588 602 20471717
6. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. N Iwata, S Tsubuki, Y Takaki, K Watanabe, M Sekiguchi, E Hosoki, M Kawashima-Morishima, HJ Lee, E Hama, Y Sekine-Aizawa, TC Saido, Nat Med 2000 6 143 150 10.1038/72237 10655101
7. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. MA Leissring, W Farris, AY Chang, DM Walsh, X Wu, X Sun, MP Frosch, DJ Selkoe, Neuron 2003 40 1087 1093 10.1016/S0896-6273(03)00787-6 14687544
8. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. A Caccamo, S Oddo, MC Sugarman, Y Akbari, FM LaFerla, Neurobiol Aging 2005 26 645 654 10.1016/j.neurobiolaging. 2004.06.013 15708439
9. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. S Wang, R Wang, L Chen, DA Bennett, DW Dickson, DS Wang, J Neurochem 2010 115 47 57 10.1111/j.1471-4159.2010.06899.x 20663017
10. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. RA Marr, E Rockenstein, A Mukherjee, MS Kindy, LB Hersh, FH Gage, IM Verma, E Masliah, J Neurosci 2003 23 1992 1996 12657655
11. Optimization of adeno-associated viral vector-mediated gene delivery to the hypothalamus. MW de Backer, MA Brans, MC Luijendijk, KM Garner, RA Adan, Hum Gene Ther 2010 21 673 682 10.1089/hum.2009.169 20073991
12. Gene therapy: can neural stem cells deliver? FJ Muller, EY Snyder, JF Loring, Nat Rev Neurosci 2006 7 75 84 10.1038/nrn1829 16371952
13. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. LM Billings, S Oddo, KN Green, JL McGaugh, FM LaFerla, Neuron 2005 45 675 688 10.1016/j.neuron.2005.01.040 15748844
14. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. S Oddo, A Caccamo, JD Shepherd, MP Murphy, TE Golde, R Kayed, R Metherate, MP Mattson, Y Akbari, FM LaFerla, Neuron 2003 39 409 421 10.1016/S0896-6273(03)00434-3 12895417
15. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). E Rockenstein, M Mallory, M Mante, A Sisk, E Masliaha, J Neurosci Res 2001 66 573 582 10.1002/jnr.1247 11746377
16. Retinal transplantation of neural progenitor cells derived from the brain of GFP transgenic mice. H Mizumoto, K Mizumoto, MA Shatos, H Klassen, MJ Young, Vision Res 2003 43 1699 1708 10.1016/S0042-6989(03)00235-9 12818339
17. Pathways by which Abeta facilitates tau pathology. M Blurton-Jones, FM Laferla, Curr Alzheimer Res 2006 3 437 448 10.2174/156720506779025242 17168643
18. Reciprocal connections between the amygdala and the hippocampal formation, perirhinal cortex, and postrhinal cortex in rat. A Pitkanen, M Pikkarainen, N Nurminen, A Ylinen, A review. Ann N Y Acad Sci 2000 911 369 391
19. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. S Oddo, L Billings, JP Kesslak, DH Cribbs, FM LaFerla, Neuron 2004 43 321 332 10.1016/j.neuron.2004.07. 003 15294141
20. Neural stem cells improve memory in an inducible mouse model of neuronal loss. TR Yamasaki, M Blurton-Jones, DA Morrissette, M Kitazawa, S Oddo, FM LaFerla, J Neurosci 2007 27 11925 11933 10.1523/JNEUROSCI.1627-07.2007 17978032
21. Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. B Spencer, RA Marr, E Rockenstein, L Crews, A Adame, R Potkar, C Patrick, FH Gage, IM Verma, E Masliah, BMC Neurosci 2008 9 109 10.1186/1471-2202-9-109 19014502
22. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. WJ Meilandt, M Cisse, K Ho, T Wu, LA Esposito, K Scearce-Levie, IH Cheng, GQ Yu, L Mucke, J Neurosci 2009 29 1977 1986 10.1523/JNEUROSCI.2984-08.2009 19228952
23. Enhanced proteolytic clearance of plasma abeta by peripherally administered neprilysin does not result in reduced levels of brain abeta in mice. JR Walker, R Pacoma, J Watson, W Ou, J Alves, DE Mason, EC Peters, HD Urbina, G Welzel, A Althage, B Liu, T Tuntland, LH Jacobson, JL Harris, AM Schumacher, J Neurosci 2013 33 2457 2464 10.1523/JNEUROSCI.3407-12.2013 23392674
24. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. RD Terry, E Masliah, DP Salmon, N Butters, R DeTeresa, R Hill, LA Hansen, R Katzman, Ann Neurol 1991 30 572 580 10.1002/ana.410300410 1789684
25. Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. JP Awe, PC Lee, C Ramathal, A Vega-Crespo, J Durruthy-Durruthy, A Cooper, S Karumbayaram, WE Lowry, AT Clark, JA Zack, V Sebastiano, DB Kohn, AD Pyle, MG Martin, GS Lipshutz, PE Phelps, RA Pera, JA Byrne, Stem Cell Res Ther 2013 4 87 10.1186/scrt246 23890092
26. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. L Lebson, K Nash, S Kamath, D Herber, N Carty, DC Lee, Q Li, K Szekeres, U Jinwal, J Koren, CA Dickey, PE Gottschall, D Morgan, MN Gordon, J Neurosci 2010 30 9651 9658 10.1523/JNEUROSCI.0329-10.2010 20660248
27. CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucemies). MC Bene, GC Faure, Haematologica 1997 82 205 210 9175328
28. How to get from here to there: macrophage recruitment in Alzheimer's disease. K Rezai-Zadeh, D Gate, G Gowing, T Town, Curr Alzheimer Res 2011 8 156 163 10.2174/156720511795256017 21345166
29. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. JJ Palop, L Mucke, Nat Neurosci 2010 13 812 818 10.1038/nn.2583 20581818
30. A network diffusion model of disease progression in dementia. A Raj, A Kuceyeski, M Weiner, Neuron 2012 73 1204 1215 10.1016/j.neuron.2011.12.040 22445347